Effect of Immunosuppressive Therapy on Clinical Outcomes for Patients With Aortic Stenosis Following Transcatheter Aortic Valve Implantation
Open Access
- 25 November 2020
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (12), 2296-2301
- https://doi.org/10.1253/circj.cj-20-0600
Abstract
Background:Transcatheter aortic valve implantation (TAVI) is an established treatment for symptomatic patients with severe aortic stenosis (AS). Sometimes patients with severe AS taking immunosuppressants are encountered. The effect of immunosuppressive therapy on clinical outcomes in patients with AS following TAVI were investigated. Methods and Results:In total, 282 consecutive patients with severe AS who underwent transfemoral TAVI from January 2016 to December 2018 at St. Marianna University School of Medicine were reviewed. They were divided into 2 groups: the immunosuppressants group (IM group) in which patients continually used immunosuppressive drugs (n=22) and the non-immunosuppressants group (non-IM group) (n=260). The composite endpoints of a major adverse cardiovascular and cerebrovascular event (MACCE) defined as non-lethal myocardial infarction, unstable angina pectoris, heart failure requiring hospitalization, stroke, and cardiovascular death were evaluated. There were no differences in the incidence of vascular access complications (32% vs. 20%, P=0.143) and the rate of procedure success (100% vs. 93%, P=0.377) between the IM and non-IM groups. During the median follow-up period of 567 (16–1,312) days after the TAVI procedure, there were no significant differences between the IM and non-IM groups in the incidence of infectious complications (14% vs. 9%, P=0.442) or MACCE (18% vs. 20%, respectively; P=0.845). Conclusions:The use of IM after TAVI is not associated with increased vascular access complications or mid-term MACCE in patients with severe AS treated with TAVI.Keywords
This publication has 16 references indexed in Scilit:
- Transcatheter aortic valve implantation in patients on corticosteroid therapyHeart and Vessels, 2017
- Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of EchocardiographyJournal of the American Society of Echocardiography, 2017
- Vascular complications in steroid treated patients undergoing transfemoral aortic valve implantationCatheterization and Cardiovascular Interventions, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Peripheral Vascular Complications During Transcatheter Aortic Valve Replacement: Management and Potential Role of Chronic Steroid UsePerspectives in Vascular Surgery and Endovascular Therapy, 2012
- Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document†European Heart Journal, 2012
- Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritisArthritis Care & Research, 2006
- Systemic corticosteroid therapy---side effects and their managementBritish Journal of Ophthalmology, 1998
- Surgical Management of Complications of Steroid TherapyAnnals of Surgery, 1977
- Tissue effects of glucocorticoidsThe American Journal of Medicine, 1972